Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

A technology of compounds and alkyl groups, applied in the direction of drug combination, medical preparations containing active ingredients, organic chemistry, etc.

Inactive Publication Date: 2015-12-23
SIGNAL PHARMA LLC
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, TNBC remains a major challenge for physicians and patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0266] Example 1: 2,4-dichloro-5-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine

[0267]

[0268] 2,4-dichloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine. With 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (950g, 5053mmol) and DCM (16 L) to fill a 50-L jacketed reactor. The resulting tan suspension was cooled to 16°C and N-iodosuccinimide (1598 g, 7104 mmol) was added portionwise over 20 minutes. The reaction mixture was stirred at room temperature for 16 hours, after which time TLC analysis (2:1 hexane / ethyl acetate) indicated that the reaction was complete. The resulting precipitate was filtered, washed with DCM (3x1.5L), and dried under reduced pressure at 40°C for 64 hours to afford 1447g (yield: 91%) of the title compound as a beige solid. MS(ESI)m / z314.0[M+1] + .

[0269] 2,4-Dichloro-5-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine. Flush with nitrogen and wash with 2, 4-Dichloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1437g, 4578mmo...

Embodiment 2

[0270] Example 2: 4-(4-(cyclopentylamino)-5-(4-hydroxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy -n-methylbenzamide

[0271]

[0272] 2-Chloro-N-cyclopentyl-5-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-4- Amine. 2,4-dichloro-5-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (1 equivalent) , cyclopentylamine (1 equiv), sodium tert-butoxide (7.5 equiv) and 1,4-dioxane (0.28M) were combined in a sealable container with a stir bar. The resulting mixture was placed under a nitrogen atmosphere, sealed, stirred vigorously, and heated at 70°C. After cooling to room temperature, the reaction mixture was directly loaded onto a silica gel column and purified by flash chromatography (Biotage) (0-20% ethyl acetate in hexanes) to give the title compound as a yellow solid (94% yield ). MS(ESI)m / z459.3[M+1] + .

[0273] 4-(2-Chloro-4-(cyclopentylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5 -yl...

Embodiment 3

[0276]Example 3: 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidine -2-yl)amino)-3-methoxy-N-methylbenzamide

[0277]

[0278] 2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole. Will be contained in 1,4- A suspension of 6-bromo-2-methylbenzo[d]oxazole (1 eq), bis(pinacolate) diboron (2 eq), potassium acetate (3 eq) in dioxane was treated with argon Degas for 10 minutes. Then, 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane adduct (0.05 equiv) was added and the solution was further degassed with argon for 10 minutes. The reaction mixture was heated at 110°C overnight. The reaction mixture was cooled to room temperature, the solvent was removed under reduced pressure and the crude product was purified by column chromatography (100-200 mesh silica gel; 0-10% ethyl acetate in n-hexane as eluent) to afford the title compound. (Yield: 34%), MS (ESI) m / z 260 [M+1] + .

[0279] 4-Amino-3-methoxy-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Description

[0001] This application claims the benefit of US Provisional Application No. 61 / 753,259, filed January 16, 2013, which is hereby incorporated by reference in its entirety. technical field [0002] Provided herein are certain pyrrolopyrimidine compounds; compositions comprising effective amounts of such compounds; and methods for treating or preventing breast cancer, especially triple negative breast cancer, comprising administering to a subject in need thereof an effective amount of such pyrrolopyrimidine compounds. Background of the invention [0003] Every year, more than 1.3 million new cases of breast cancer are diagnosed around the world. Despite advances in prevention, surgical resection, chemotherapy, and targeted therapy over the past decade, it is estimated that approximately 450,000 women worldwide will die from the disease each year. Triple-negative breast cancer (TNBC) is a subtype encompassing a heterogeneous subgroup of tumors sharing three defining features: ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519C07D487/00A61P35/00
CPCC07D487/04A61K31/519A61K31/5377A61P35/00A61P35/04C07D471/04
Inventor 安德鲁·安东尼·卡拉布雷斯布兰登·杰菲戴尔·罗宾逊丹·朱黄德华简·埃尔斯纳约翰·博伊兰琳达·泰赫拉尼马克·A·纳吉拉杰·库马尔·拉赫加保罗·厄尔德曼拉玛·K·娜尔拉洛伊·L·哈瑞斯塔姆·明·特朗詹尼弗·里格斯宁余红徐水蟾
Owner SIGNAL PHARMA LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com